Objective: Type III endoleaks (T-III) following endovascular repair of aortic aneurysms (EVAR) remain a major concern. Our center experienced a recent concentration of T-III endoleaks requiring elective and emergency treatment and prompted our review of all EVAR implants over a 40 month period from April 2011 until August 2014. This report represents a single center experience with T-III endoleak management with analysis of factors leading to the T-III related failure of EVAR.
Results:
Overall technical success and discharge survival was achieved in 97.3% and 98% of patients regardless of device usage. There was no significant device related difference identified between patient survival or freedom from intervention. Major adverse events involving aneurysm treatment were over 7 fold more frequent with ELX (Group1) vs non-ELX (Group 2) endografts (p<0.01). Group 1 patients with aneurysm diameters larger than 65 mm were associated with a highly significant value for development of a T-III endoleak (OR=11.16, 95% CI (2.17, 57.27); p=0.0038).
Conclusions:
While EVAR technical success and survival was similar across all devices, ELX devices exhibited an unusually high incidence of Type III endoleaks when implanted in AAA with a diameter of more than 65 mm. Frequent reinterventions were required for Endologix devices for prevention of aneurysm rupture due to T-III endoleaks.
INTRODUCTION: Endovascular management of abdominal aortic aneurysms (EVAR) has
become an accepted form of repair since the initial report by Parodi 1 . In 2009, the Division of Vascular Surgery at Indiana University initiated a Level 1 Acute Aortic program designed to centralize rapid response, transport and treatment of aortic emergencies within the state of Indiana and surrounding area. All FDA approved and commercially available devices were used in our practice with preponderance of the use of Endologix endografts. In 2013, a concentration of reinterventions for Type III (T-III) endoleak treatment raised concern over device selection and prompted a review of all patients having EVAR repair with FDA approved endografts.
Methods:
Using SVS/AAVS reporting standards, we obtained variables from the index procedure which included timing of repair, AAA neck and sac morphology, age, medical comorbidities, correlation of AAA repair with manufacturer's instructions for use, technical success and presence of endoleak at the completion of the procedure 2 .
Indications for EVAR repair included all standard indications and specifically symptomatic or ruptured AAA; elective AAA size exceeding 5.5 cm in a male and > 5 cm in a female; saccular aneurysms regardless of size; enlarging aneurysms with size increase of > 0.5 cm in 6 months; atheroembolism attributed to aneurysmal disease and pre-transplant patients having AAA exceeding 3 cm (as per protocol). Technical success was defined as satisfactory endograft placement with exclusion of the aneurysm sac, maintaining patent renal vessels and absence of Type I or Type III endoleaks at the completion of the procedure. Mortalities were reviewed from medical records and from last known contact to determine if they were device related. For analysis, patients receiving an endograft from Endologix (Powerlink or AFX -Irvine, CA) were identified as Group 1. Patients receiving endografts from Gore (Excluder-Flagstaff, AZ), Cook (Zenith-Bloomington, IN) or Medtronic (Endurant-Minneapolis, MN) manufacturers were identified as Group 2. AAA freedom from re-intervention was assessed at any point of aneurysm reintervention as a binary numeral. Patient survival was documented at completion of the index procedure, at any re-intervention and from last available patient contact.
Freedom from intervention was defined as the absence of any singular event required for aneurysm treatment and independent of the number of reinterventions encountered. Any indication for aneurysm treatment, timing of repair, repair method and procedural success was noted. Major Adverse Events (MAE) defined the cumulative sum of events involving any device related mortality + post-implant aneurysm rupture + any operative conversion and all aneurysm reinterventions required to maintain freedom from aneurysm rupture. Major adverse events were then tabulated for each group and independently for each patient. . This study met requirements for Indiana University IRB expedited review with patient consent waived. Statistical analysis was performed using SAS version 9.4 (SAS Institute, Inc. Cary, NC.). Odds Ratios for Type III endoleak occurrence, Chi square and Fischer's Exact test to account for low expected cell counts were used in univariate analysis of patient reinterventions. Pre-operative and procedural variables were submitted for ANOVA and multivariable-logistic regression analysis. KaplanMeier curve was used to plot patient survival. All analytic assumptions were verified to ensure results validity. A p value less than 0.05 was considered statistically significant.
RESULTS:
There were a total of 151 patients, 83 having an ELX endograft (Group 1) while 68 received a Cook, Gore or Medtronic device (Group 2). Table I One hundred thirty two patients were alive at the completion of the study; Group 1= 71, Group 2 = 61 (p=0.3025).
Technical success was achieved in 97.3% (147/151) for EVAR placement, with no difference between either group (p = 0.2525). Similarly, over 98% of patients were discharged alive following their EVAR procedure. There were four deaths that occurred during the index hospital stay: three from aneurysm rupture and one from operative conversion for an unresolved Type Ia endoleak. Over the course of the study, eighteen deaths were recorded with twelve in Group 1 and six in Group 2 (p=0.2451 overall). Table II Four mortalities were deemed device related (DR) which included one operative conversion during the index hospital stay and three deaths following emergent reintervention treatment, all in Group1 (p =0.1274).
No statistical significant difference was noted when the following variables were compared per group: sex, age, pre-op co-morbidity risk factors, and timing of repair, AAA size, or choice of endograft.
Survival analyses indicate that there were no significant differences in the time until death or re-intervention from surgery (p>0.05). In contrast to all other endograft designs, the ELX endoskeleton can prove challenging with reinterventions to avoid wireframe entrapment. Currently no evidence exists as to whether repair of T-III endoleaks should be accomplished with like (similar) devices or with alternative endograft products. Both techniques were utilized in this series and similar outcomes were noted.
The Endologix endoskeletal design for both Powerlink and AFX stent grafts provide maximum flexibility in conforming to AAA morphology. The bifurcated unibody design, ease of length adjustment for overlap at the time of implant and rapid deployment system allow for elective, urgent and emergent AAA repair with one sheath delivery. Several reports have documented its safety record in longitudinal AAA care 7, 8, and 9 . Flexibility in the endoskeletal design, however, may be detrimental to lateral stability especially when a large diameter aneurysm is treated as distraction forces impact component overlap to a greater degree than caudal or cephalad migration of aortic and iliac seal zones. We hypothesize that fabric billowing of the proximal aortic extension may provide a reverse windsock effect that increases distraction forces between the bifurcated unibody stent graft and the proximal aortic extension by cephalad displacement that can ultimately cause an uncoupling of the two components. This appears more pronounced with aneurysms of larger size (65mm) and may be accentuated when diameters of the bifurcated unibody stent graft and the aortic extension differ significantly. The mean AAA size for patients with TIIIa endoleak in this study was 80.5 mm. All six patients experiencing T-IIIa in this report had a 25 or 28 mm diameter bifurcated unibody stent graft coupled with a 34 mm proximal aortic extension.
Similar to prior reports, we found no difference between patient survival and freedom from any intervention between the two groups 4, 10, 11, 12 . Significant differences were noted between Groups for Aortic Neck diameter (p =0.0179), Aortic neck length (p= 0.0016), Aortic neck angle (p = 0.0101) and Aneurysm angle (p =0.0045) measurements. All of these values are well within the IFU recommendations of all devices used, so clinical relevance of these values is uncertain.
While there was no difference between Groups in freedom from reintervention , we found a large difference in MAE's not previously reported as several of our patients experienced more than one MAE at different episodes of treatment (range 0-5) (p< 0.0001). Post implant rupture rate and AAA reintervention proved to be also highly significant between Groups.
While not statistically significant, all T-IIIa patients in this series did develop increasing centerline measurements and decreasing component overlap prior to IIIa endoleak discovery. This is likely due to the extended length of follow up imaging obtained during routine surveillance for stable aneurysms. Our 7.2% (6/83) incidence of T-IIIa is more than double that 
